Clene (NASDAQ: CLNN) Developing Breakthrough Treatment for Neurodegenerative Diseases
Clene (NASDAQ: CLNN) Developing Breakthrough Treatment for Neurodegenerative Diseases
Key Takeaways (TLDR)
Clene's focus on improving mitochondrial health with CNM-Au8 gives them an advantage in treating neurodegenerative diseases.
CNM-Au8 targets the nicotinamide adenine dinucleotide pathway to restore and protect neurological function in ALS, MS, and Parkinson's disease.
Clene's innovative treatment offers new hope for patients with neurodegenerative diseases, making tomorrow better than today.
The global therapeutics market for neurogenerative diseases is projected to grow substantially, driven by new therapies and a rising geriatric population.
Why it Matters
This news matters because Clene's innovative treatment, CNM-Au8, offers new hope for patients with ALS, MS, and Parkinson's disease. The company's focus on improving mitochondrial health and targeting the NAD+ pathway has the potential to transform the treatment of neurodegenerative diseases, impacting millions of people worldwide.
Summary
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, is making significant strides with its lead candidate, CNM-Au8. This innovative treatment focuses on targeting the nicotinamide adenine dinucleotide (NAD+) pathway, which is critical for many mitochondrial functions, including energy production and redox homeostasis. Through this novel mechanism, CNM-Au8 restores and protects neurological function, offering new hope for patients with conditions like amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and Parkinson’s disease. Clene is preparing Phase 3 trials of CNM-Au8 in MS and ALS.
This news story relied on a press release distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Clene (NASDAQ: CLNN) Developing Breakthrough Treatment for Neurodegenerative Diseases.